

A case study wistar rats by implementing Metformin on Clozapine

Vinaya B*, Akila CR, Dinesh Babu J, Sravan Kumar P

Department of Pharmacology, Scient Institute of Pharmacy, Ibrahimpatnam, Hyderabad-501506, Telangana, India

Article History:

Received on: 14 Feb 2018
Revised on: 05 Mar 2018
Accepted on: 16 Mar 2018
Published on: 26 Jun 2018

Volume: 8 Issue: 1

Keywords:

Clozapine,
pharmacotherapeutic
Metformin,
Second generation
antipsychotics
Dyslipidaemia.

ABSTRACT

The medical studies in beyond decade has reported that maximum 2nd-era antipsychotics (SGAs) can reason severe metabolic derangement, which significantly upsurges the danger for type II diabetes mellitus. Numerous retrospective studies have proven multiplied in serum triglyceride in sufferers handled with Clozapine. SGAs triggered metabolic syndrome is characterized via hypertension, weight gain, hyperglycaemia, hyperlipidaemia, glucose intolerance and insulin resistance. Metformin is presently used to extravagance metabolic syndrome and type II diabetes mellitus. It is consequently essential to decide whether Metformin is effective in discussing Clozapine-brought on metabolic derangement like dyslipidaemia. To appraise the impact of Metformin in minimizing Clozapine caused metabolic irrationality like dyslipidaemia. Methodology: Wistar rats weighing a hundred and eighty-240g both intercourse had been divided into three corporations of 6 rats every. Group 1 attended as manipulate, Group 2 Preserved with Clozapine 25mg/kg frame weight and Group 3 Treated with Clozapine 25mg + Metformin 100mg/kg body weight for 30 days P.O. Group 2 and group three were preserved for 30 days. Lipid profile of institution 2 rats handled with Clozapine showed dyslipidaemia (TG 103.3 ± 1.7 mg/dl, Tc 113.7 ± 1.6 mg/dl). Whereas organization 3 rats treated with Clozapine 25mg + Metformin confirmed ordinary lipid levels (TG ninety four.7 ± 1.7 mg/dl, TC 102.Eight ± 0.8 mg/dl) similar to institution 1 (TG ninety three.0 ± 2.6 mg/dl, TC 103.7 ± 1.5 mg/dl). This study focuses a non-substantial increase in fasting blood glucose in SD rodents managed with clozapine that was in part checked by utilizing simultaneous organization of metformin. Rodents controlled clozapine affirmed the anticipated abatement in the statement of GLUT2, anyway simultaneous administration of metformin and clozapine for 30 days didn't show the anticipated standardization of the articulation degrees of GLUT2. This look at investigating the use of Metformin to forestall metabolic unsettling like dyslipidaemias in patients of schizophrenia managed with Clozapine.



*Corresponding Author

Name: Vinaya B
Phone: 9100431230
Email: vinnu.kanni1@gmail.com

eISSN: 2277-4149

DOI: <https://doi.org/10.26452/irjpas.v8i1.1309>



Production and Hosted by

ScienZTech.org

© 2018 | All rights reserved.

INTRODUCTION

In this segment represents introduction of this research work. In recent years Second generation antipsychotics (SGAs) are effective pharmacotherapeutic agents for various neuropsychiatric diseases, especially Schizophrenia, but also for bipolar disorder, autism, as a add on therapy in many major depressive disorders and are used by millions of patients in the world [1-4]. The major advantage of these drugs is that they are less likely to cause neuro-

logic side effects. The neurologic side effects of first-generation antipsychotics (FGAs) are due to potent dopamine D2 receptor blockade and are important limiting factors for long term use of these agents [5-7]. The second-generation antipsychotics (SGAs) are presently more arranged outstanding to lack of these neurological side belongings. SGAs act both 5HT2 and are weak D2 blocker. In addition, they have alpha adrenergic blocking, anticholinergic and H1 antihistaminic activity.

A massive range of research have discovered a robust association among antipsychotic medications and lessened glucose metabolism and diabetes. Patients with psychosis who use antipsychotics for long durations have a higher prevalence of diabetes in comparison to the general population. Incidence of impaired glucose metabolism varies widely across antipsychotics with different chemical structures. [8-10]The clozapine and olanzapine were connected with the largest weight gain and the highest risk of abnormal glucose metabolism compared to other atypical antipsychotics. Despite its popularity due to its effectiveness in difficult-to-treat patients and its lower incidence of extrapyramidal side-effects, tardive dyskinesia and elevated prolactin than other atypical antipsychotics, concerns about the association of clozapine with weight gain, increased blood glucose and type II diabetes [11-13] has limited its clinical use. This issue is of particular interest in China because of the frequent use of clozapine as monotherapy or in grouping with other antipsychotic negotiators in the conduct of schizophrenia. [14, 15]

In these articles represents sector 2 of these articles explains the feature on the related works. In section 3 presents the materials and methods adopted and section 4 presents the particulars of the experiments and discussions. Finally segment 5 accomplishes the articles by allocation our implications and upcoming strategies.

RELATED WORKS

In this segment represents focuses the related works of this research work. Animal studies can help understand the molecular mechanisms underlying the antipsychotic-induced abnormalities in glucose metabolism and the ameliorating effect of metformin on these side-effects. One such study [16] Located that clozapine repressed insulin emission of isolated pancreatic islets in rats and, accordingly, resulted in improved blood glucose. The cutting-edge have a look at compares the stages of numerous variables among 3 businesses of rats administered clozapine, clozapine and metformin or

saline for 30 days: fasting blood glucose, insulin, C-peptide, and mRNA and protein tiers of the glucose transporter-2 (GLUT2) in pancreatic β cells.

The clinical research in past decade Has pronounced that most SGAs can reason severe metabolic detrimental consequences like dyslipidaemia, ensuing in a metabolic syndrome that significantly increases the hazard for aerobic-metabolic disorders, which include kind II diabetes mellitus and cardiovascular diseases [17].

Several studies have reported that there is augmented loss of life in patients with Schizophrenia. Besides, they have higher risks for cerebrovascular illnesses, respiratory disorders and mortality from suicide. However, the most common reason for death suggested to be cardiovascular disorders [18]. With widespread use of these drugs, the metabolic adverse Effects of antipsychotics are a major public health problem and there is a fantastic need for a higher knowledge for their management. Consistent with the literature on kind II diabetes mellitus, some achievement has been acquired via lifestyle adjustments, along with workout and nutritional modifications [19].

There have been several research papers about this issue in China. Clinical trials have demonstrated that metformin can effectively reduce the side effects of antipsychotics (particularly those caused by clozapine and olanzapine) including weight gain, increased blood glucose and other metabolic abnormalities. The metformin can effectively mitigate antipsychotics-induced weight gain and abnormal glucose metabolism and several other studies in China report similar findings. [20]A meta-evaluation mentioned and discovered that metformin can lessen weight, frame mass index (BMI), waist circumference and insulin fighting, but did no longer lessen the occurrence of diabetes in patients the usage of antipsychotics.

However, these adjustments can be greater challenging inside the psychiatric population, therefore the mainstay of remedy stays using antidiabetic drug like Metformin to minimise or to ameliorate metabolic derangement like dyslipidaemia. Metformin is being presently used to deal with metabolic syndrome and sort II diabetes mellitus. Metformin acts through diverse pharmacological mechanisms. Metformin has been demonstrated to diminish the incidence of type 2 diabetes mellitus by 31% compared to control subjects who received placebo. The present study proposes that reduced progression from pre-diabetes to diabetes should be a treatment goal for patients with Schizophrenia treated with SGAs. Regular use of Metformin

would be expected to lower the progression rate to a considerable extent. It is therefore significant to regulate whether Metformin is effective in giving SGAs encouraged metabolic derangement like dyslipidaemia. Consequently, the current study is undertaken to appraise the effects of Metformin on metabolic derangement like dyslipidaemia caused by Clozapine, a SGA drug in a rat model.

MATERIALS AND METHODS

In this section gives the substances and methods of this studies work. Study layout: An Experimental animal-primarily based observe.

Ethics approval: The take a look at became reviewed and accepted by the Institutional Animal Ethics Committee (IAEC)vide letter reference number; 665/15, dated 07.12.2015. Study was executed as in keeping with recommendations of Committee for the Purpose of Control and Supervision of Experimentation on Animals (CPCSEA).

Locus of study: BLDEU's Shri B.M. Patil Medical College Hospital & Research Centre, Vijayapur.

Sample length: 18 Wistar rats

Methodology: Wistar rats weighing 180-240g both sex bred from a stock received from Chennai, were used within the have a look at. Animals had been housed in separate room three each in polypropylene cages for one week acclimatization earlier than the start of the look at. The cages were covered with paddy husk which changed into replaced every day and animals have been saved below wellknown situation of illumination with a 12 - h mild-darkish cycle at room temperature of $25 \pm 1^\circ \text{C}$ and forty five-70% relative humidity. The animals were fed with business pellet rat chow and water advert libitum. Dose calculation: Rat dose in line with day is calculated using common human dose/day and transformed into rat dose the usage of following formula: $\text{Rat dose}/200\text{g} = \text{human dose} \times \text{zero}.18$.

Grouping of animals, dose of drug and path of management:

Animals will be divided into 3 groups of six rats every, each group having equal wide variety of male and girl rats.

Group 1: Control (n=6) became given distilled water p.O

Group 2: Received Clozapine (n=6)25mg/kg p.O [10]

Group 3: Received Clozapine25mg/kg + Metformin 100mg/kg p.O [11]

All animals had access to food and water advert libitum.

Dyslipidaemia: Group 2 rats handled with Clozapine for 28days to supply dyslipidaemia. Whereas group 3 rats handled with Clozapine 25mg + Metformin 100mg/kg consistent with P.O. For 28days.

Sample series: Retro-orbital blood was collected for Lipid profile.

Parameters studied: Triglycerides, Total Cholesterol, HDL, LDL, VLDL via vehicle analyser approach

Statistical evaluation: All the values have been expressed because the suggest \pm SEM and analysed by using one-manner analysis of variance (ANOVA) so as to test alterations among corporations. The level of arithmetical consequence has been set at $p < 0.05$.

RESULTS AND DISCUSSIONS

In this phase focuses the outcomes and discussions of this research work. The statistically good sized increase in serum stages of Triglycerides, Total cholesterol, LDL and VLDL ranges as associated to those in normal manipulate institution over observe duration. Administration of Clozapine alongside Metformin in Group 3 (Clozapine + Metformin dealt with rats) there was no such statistically significant growth and became akin to the ones rats in untreated manipulate group. The prevalence of diabetes mellitus has been shown to be extended in patients dealt with with SGAs in contrast with popular populace [12]. Several retrospective studies proven extended in serum triglyceride in patients treated SGAs like Clozapine [13].SGAs capsules caused metabolic syndrome is characterised with the aid of weight advantage, hyperprolactemia, hyperlipidaemia, hyperglycaemia, glucose intolerance, hypertension cardiovascular disease and insulin resistance [14]. For the sufferers who are taking Clozapine, the hazard of unindustrialized type 2 diabetes all through the primary 6 years is finest. It has been suggested that the various patients who took Second era antipsychotic like Clozapine greater than 50% end up obese [15]. Treatment with Clozapine become related to a median weight advantage of 9.8lb over 10weeks which is as high as any other antipsychotics [11]. In one of the studies the prevalence of metabolic syndrome has been found to be as high as 24.6% [16]. Metabolic syndrome is likewise predictive of each cardiovascular diseases and kind 2 diabetes mellitus. This may result in early dying [15].These metabolic adjustments are visible no matter age, intercourse or length of antipsychotic therapy [17, 18].

In our take a look at there was a statistically con-

siderable growth in serum stages of TG, TC, LDL and VLDL in Group 2 as compared to institution 1. While in Group 3(dealt with with Clozapine + Metformin) there has been no significant boom in TG, TC, LDL and VLDL similar effects had been stated by Chen C et al (2013), He studied effects of adjunctive Metformin on metabolic derangement in non-diabetic schizophrenic sufferers handled with Clozapine and discovered that Metformin considerably reversed the metabolic derangement specifically due to its effect on triglycerides caused by Clozapine. Metformin also reduced frame weight considerably. However, beneficial effect of Metformin on body weight in Clozapine handled sufferers disappeared on discontinuation of Metformin. Metformin is well tolerated with the aid of those patients. Thus, it helps the approach for long term Metformin supplementation in Clozapine dealt with patients with Schizophrenia and pre-existing metabolic abnormalities [19]. In our observe there was no enormous trade in serum HDL degrees and those are also comparable with take a look at performed through Ozenoglu et al [20] and he also did no longer record any giant changes in serum tiers of HDL.

CONCLUSION

Finally this work concludes, that Metformin reverses the metabolic derangement like dyslipidaemia caused by Clozapine in Wistar rats. This raises the possibility that Metformin supplementation can be considered to improve metabolic derangement like dyslipidaemia in treated with Clozapine. Careful monitoring of risk patients may help in the prevention of metabolic derangements as well as the management of any possible symptoms which they occur.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

Funding Support

The authors declare that they have no funding support for this study.

ACKNOWLEDGEMENT

The authors are thankful to all who have extended their constant support for the completion of the work.

REFERENCES

[1] Honer WG, Thornton AE, Sherwood M, MacEwan GW, Ehmann TS, Williams R, et al. Concep-

tual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. *CNS Drugs*. 2007;21(9):699-714. Available from: [10.2165/00023210-200721090-00001](https://doi.org/10.2165/00023210-200721090-00001).

- [2] Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. *Schizophrenia Bulletin*. 2012;38(1):167-177. Available from: [10.1093/schbul/sbq042](https://doi.org/10.1093/schbul/sbq042).
- [3] Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. *British Journal of Psychiatry*. 2010;197(4):266-271. Available from: [10.1192/bjp.bp.109.076935](https://doi.org/10.1192/bjp.bp.109.076935).
- [4] Liu HP. Effects of metformin hydrochloride on body mass and blood sugar of inpatients with schizophrenia on clozapine. *J Clin Psychosom Dis*. 2012;18(2):97-100.
- [5] Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. *British Journal of Psychiatry*. 2000;177(3):212-217. Available from: [10.1192/bjp.177.3.212](https://doi.org/10.1192/bjp.177.3.212).
- [6] Park T, Usher K, Foster K. Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. *International Journal of Mental Health Nursing*. 2011;20(6):428-437. Available from: [10.1111/j.1447-0349.2011.00747.x](https://doi.org/10.1111/j.1447-0349.2011.00747.x).
- [7] von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. *Acta Psychiatrica Scandinavica*. 2009;119:15-21. Available from: [10.1111/j.1600-0447.2008.01309.x](https://doi.org/10.1111/j.1600-0447.2008.01309.x).
- [8] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393-403.
- [9] Hafidh S, Senkottaiyan N, Alpert MA, Villarreal D. Management of the Metabolic Syndrome. *The American Journal of the Medical Sciences*. 2005;330(6):343-351. Available from: [10.1097/00000441-200512000-00013](https://doi.org/10.1097/00000441-200512000-00013).
- [10] Eman A, A. Histopathological change of the endocrine pancreas, in male Albino rat treated Atypical Antipsychotic Clozapine. *Rom J Morphol Embryol*. 2013;54(2):385-394.
- [11] Cheng JT, Huang CC, Liu IM, Tzeng TF,

Chang CJ. Novel Mechanism for Plasma Glucose-Lowering Action of Metformin in Streptozotocin-Induced Diabetic Rats. *Diabetes*. 2006;55(3):819-825. Available from: [10.2337/diabetes.55.03.06.db05-0934](https://doi.org/10.2337/diabetes.55.03.06.db05-0934).

- [12] Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. *J Clin Epidemiol*. 2003;56:164-70.
- [13] Hasnain M, Vieweg WVR, Hollett B. Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians. *Postgraduate Medicine*. 2012;124(4):154-167. Available from: [10.3810/pgm.2012.07.2577](https://doi.org/10.3810/pgm.2012.07.2577).
- [14] Henderson DC. Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study. *American Journal of Psychiatry*. 2000;157(6):975-981. Available from: [10.1176/appi.ajp.157.6.975](https://doi.org/10.1176/appi.ajp.157.6.975).
- [15] Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. *The American Journal of Medicine*. 2001;111(9):716-723. Available from: [10.1016/s0002-9343\(01\)01000-2](https://doi.org/10.1016/s0002-9343(01)01000-2).
- [16] Chen J, Feng F, Shang L, Li J, Han XQ, Pang Y. Assessment of medication status of elderly hospitalized patients with schizophrenia. *Journal of Psychiatry*. 2008;21(3):222-223.
- [17] Wu RR, Zhao JP, Shao P, He YQ, Fang MS, Liu YJ. Efficacy of behavioral intervention and metformin in the treatment of antipsychotic-induced weight gain and glucose metabolism dysfunction. *Chin J Psychiatry*. 2007;40(4):193-196.
- [18] Wu RR, Zhao JP, Shao P. Metformin addition therapy attenuates olanzapine-induced weight gain. *Chin J Psychiatry*. 2008;41(1):1-4.
- [19] Li CY, Pei SJ, Guo YH. Metformin in patients with schizophrenia early intervention study of glucose. *China Clinical Practical Medicine*. 2009;3(7):22-25.
- [20] Chen JX, Wu SY, Lin R, Chen HE. The efficacy of metformin in combination with life style intervention on body weight, blood lipid and blood glucose in schizophrenia during clozapine treatment. *Sichuan Mental Health*. 2010;23(4):198-202.

ABOUT AUTHORS



Vinaya B

Department of Pharmacology, Scientist Institute of Pharmacy, Ibrahimpatnam, Hyderabad-501506, Telangana, India

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Cite this article: B Vinaya, CR Akila, J Dinesh Babu, P Sra-
van Kumar. **A case study wistar rats by implementing Met-
formin on Clozapine.** *Int. Res. J Pharm. App. Sci.* 2018; 8(1):
5-9.

ScienZTech

© 2018 ScienZTech.org.